Repair Therapeutics

Over 90% of gene therapy clinical trials fail at the moment. The reasons for failure include adverse effects and low efficacy of the treatment. One of the most significant challenges in gene therapy is the difficulty in targeting transgene expression in specific tissues. One of the factors that control transgene expression is the gene regulatory element. However, optimization of this component is often neglected. This limitation may halt the progression of gene therapy development. The market currently lacks a highly accurate and selective gene therapy products. Our team has developed an algorithm to design cell-type specific gene regulatory elements for gene therapy products in several hours. Currently, biotech and pharmaceutical companies spend lots of time and money on gene therapy development, although there are a lot of risks associated with the field.